From 1 December 2022, BYETTA® (exenatide) 5mcg (AUST R 123609, PBS item code 3423E) and BYETTA® (exenatide) 10mcg (AUST R 123610, PBS item code 3424F) pre-filled pens will be discontinued from the Australian market due to discontinuation of global supply.
This discontinuation was planned prior to the supply challenges that the once-weekly glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are experiencing in Australia.
As a result of these supply challenges and the significant increase in demand for BYETTA®, the remaining BYETTA® supplies in Australia have been depleted faster than anticipated. The discontinuation date for BYETTA® has therefore been brought forward from 31 May 2023 to 1 Dec 2022.
If you have any clients treated with BYETTA® pre-filled pens, please ensure they are transitioned to another suitable treatment option.
Should you have any questions regarding this issue, please do not hesitate to contact the Astra Zeneca Medical Information Team: